Ischemic Stroke
Conditions
Keywords
acute ischemic stroke, randomized clinical trial, anterior circulation, penumbra
Brief summary
The primary objective of the study is to demonstrate that SPG (Sphenopalatine Ganglion) stimulation started within 6 hours from stroke onset slows the expansion of the infarct core volume in acute ischemic stroke.
Detailed description
The goal of this study is to identify Acute Ischemic Stroke patients who have a potentially salvageable penumbra and to test if 6 hours of SPG (Sphenopalatine Ganglion) stimulation may freeze the volume of the penumbra and reduce the extent of tissue death. Following a minimally-invasive implantation of the ISS injectable implant, patients will be randomized to either the Treated or Control arm in a 1:1 ratio. Randomization will be dynamic according to the patient's baseline covariates of core volume, total volume, Hypoperfusion Intensity Ratio (HIR), time to baseline imaging, age, NIHSS. Patients in the Treated arm will be treated with active SPG stimulation while patients in the Control arm will undergo sham treatment. After treatment/sham treatment, patients in both groups will undergo a follow up brain non-contrast CT, CT perfusion and CT angiography imaging, 6:45hrs±15min after baseline CTP initiation. In the case the patient is cooperative, hand strength (pinch and grasp) evaluations should be assessed before and during the 1st treatment/ sham SPG stimulation session. Following the assessment of the penumbra (after 6 hours) patients will be treated or sham treated for 5 additional consecutive sessions (4 hours each), the first starting within 18-24 hours from stroke onset and the others 18-26 hours from previous treatment initiation and will be followed for 90 days to assess their clinical outcome. In one session (preferably at day 2) Common Carotid Doppler examination is performed to evaluate blood flow dynamics before and during the treatment/sham session. After the last treatment session, the implant is removed.
Interventions
DEVICESPG stimulation
The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
Sponsors
BrainsGate
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Signs & symptoms consistent with the diagnosis of large vessel occlusion in the anterior circulation 2. Age 18-90 years 3. Baseline NIHSS ≥ 10 4. Ability to initiate treatment within 6 hours from stroke onset. Stroke onset is defined as the time the patient was last seen well. 5. Large vessel total occlusion by CTA 6. Penumbra ≥ 50ml (Difference between Tmax6 volume and the ischemic core volume (CBF\<38% volume) 7. Mismatch (Tmax6 volume/ischemic core volume (CBF\<38% volume) ≥1.5 8. Core and HIR (Tmax10 / Tmax6) volumes: 1. HIR ≥ 0.5 or 2. 0.35 ≤ HIR \< 0.5 and core volume/time from onset to imaging ≥ 7mililiter/hour 9. Signed informed consent from patient him/herself or legally authorized representative.
Exclusion criteria
1. Unable to undergo a contrast brain perfusion scan, including an allergy to contrast media 2. Opportunity for reperfusion therapy (IV thrombolysis or endovascular treatment) 3. Neuro-imaging evidence of any intracranial hemorrhage or hemorrhagic transformation of brain infarct or other significant abnormality (e.g. tumor, abscess, suspect for subarachnoid hemorrhage, arteriovenous malformation, cerebral aneurysm). 4. Significant mass effect with midline shift. 5. Infarct core volume \>150 milliliter 6. Old non-lacunar infarct in the anterior circulation on the ipsilateral hemisphere. 7. Previous stroke in the last 6 months or previous stroke with existing sequelae or with mRS \> 0 for any reason 8. Pre-existing Modified Rankin Score \>1, even if not stroke-related. 9. Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA/MRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion). 10. Seizures at stroke onset 11. Baseline blood glucose of \<50mg/dL (2.78 mmol) or \>400mg/dL (22.20 mmol) 12. Severe, sustained hypertension (Systolic BP \>185 mmHg or Diastolic BP \>110 mmHg) 13. Current participation in another investigational drug or device study 14. Presumed septic embolus; suspicion of bacterial endocarditis 15. Clinical signs and symptoms or evidence for a relevant lesion by neuro-imaging of an acute ischemic stroke in the posterior circulation (Vertebral, Basilar and/or Posterior Cerebral Artery territories), including but not limited to brain-stem findings and/or cerebellar findings and/or isolated homonymous hemianopia or cortical blindness. 16. Patients with bleeding propensity and/or one of the following: INR \> 1.8, prolonged activated partial thromboplastin time (aPTT) ≥ 45 sec., platelets count \< 75×10\^9/L. 17. Serious systemic infection. 18. Women known to be pregnant or having a positive or indeterminate pregnancy test. 19. Patients with other implanted neural stimulator/ electronic devices (pacemakers). 20. History of SPG ablation ipsilateral to the stroke side. 21. Any condition in the oral cavity that prevents implantation of the INS. 22. Known sensitivity to any medications to be used during study. 23. Subjects who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation. Conditions may include: cardiovascular, vascular, pulmonary, hepatic, renal or neurological (other than acute ischemic stroke), or neoplastic diseases, as determined by medical history, physical examination, laboratory tests, or ECG. 24. Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volume of core expansion | Day 1 | The primary outcome measure is the volume of core expansion (in milliliters) in 6:45h±15 min. Core expansion is the difference of two volumes: Core volume (CBF\<38%) in follow up CTP (at 6:45h±15 min) and Core volume (CBF\<38%) in baseline CTP. The difference in the mean core expansion between the Treated and Control groups will be assessed as a continuous variable with adjustment for baseline covariates (Core volume, Total volume, HIR, Time to baseline imaging). The two-sided significance level is 0.05. Handling of missing data in the primary analysis: Patients who die before the 6:45h±15 min follow-up imaging will be assigned a final core volume that equal the baseline total volume. Patients with non-interpretable follow-up imaging will be excluded from the analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in infarct volume between baseline CTP core volume and follow up NCCT infarct volume. | Day 1 | Difference in infarct volume (in milliliters) between baseline CTP core volume (CBF\<38%) and follow up 6:45h±15 min NCCT infarct volume, adjusted using stratification parameters (Core volume, Total volume, HIR, Time to baseline imaging). |
| 3 months mRS | Day 90±7 | mRS at 90-day: 1. Utility weighted mRS 2. mRS Dichotomy 0-2 3. mRS Dichotomy 0-3 |
| Difference in infarct volume between baseline CTP core volume and Day-5 NCCT infarct volume | Day 5 | Difference in infarct volume (in milliliters) between baseline CTP core volume (CBF\<38%) and Day-5 NCCT infarct volume, adjusted using stratification parameters (Core volume, Total volume, HIR, Time to baseline imaging). |
| Increased blood flow in Common Carotid Doppler | Day 2-6 | Increased blood flow in Common Carotid Doppler (if available). |
| Improvement in hand motor performance | Day 1 | Improvement in hand motor performance (if available) using a hand dynamometer (Baseline Hydraulic Hand Dynamometers, Fabrication Enterprises Inc, White Plains NY, USA). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety Data Between the Treatment and Control Arms - Symptomatic Intracranial hemorrhage (sICH) SAEs | Day 5 | Incidence of symptomatic intracranial hemorrhage (sICH) SAEs |
| Safety Data Between the Treatment and Control Arms - Pain | Day 1 to 5 | Incidence of Pain adverse events during stimulation |
| Safety Data Between the Treatment and Control Arms - Mortality | Day 90±7 | Incidence of Mortality |
| Safety Data Between the Treatment and Control Arms - Serious Adverse Events | Day 90±7 | Incidence of Serious Adverse Events |
Countries
Georgia
Contacts
Primary ContactMichael Segev
Backup ContactNoam Levy
Outcome results
None listed